Calcineurin Inhibitor- and Steroid-Free Immunosuppression in Pancreas-Kidney and Solitary Pancreas Transplantation
- 1 May 2005
- journal article
- clinical trial
- Published by Ovid Technologies (Wolters Kluwer Health) in Transplantation
- Vol. 79 (9), 1184-1189
- https://doi.org/10.1097/01.tp.0000161221.17627.8a
Abstract
Calcineurin inhibitors and steroids are standard immunosuppressants in solid organ transplantation, but (long-term) side effects are harmful to the recipient and the graft. The authors present a novel strategy for posttransplant immunosuppression that combines a depleting antibody with an antimetabolite, avoiding calcineurin inhibitors and steroids. In a prospective, nonrandomized, observational cohort study, 75 pancreas-kidney and solitary pancreas recipients received alemtuzumab (4 doses for induction and up to 12 doses within the first year) and mycophenolate mofetil (≥2 g/day) for induction and maintenance therapy. Minimum follow-up was 6 months. We compared the results with a historical group of 266 consecutive pancreas recipients on Thymoglobulin (induction) and tacrolimus (maintenance). Differences in patient and graft survival rates between the study and control groups at 6 months were not statistically significant. However, the incidence of a first reversible rejection episode was significantly higher for simultaneous pancreas-kidney recipients in the study (vs. control) group. We noted a trend toward higher modification of renal disease levels at 6 months posttransplant in the study (vs. control) groups. The combination of alemtuzumab and mycophenolate mofetil was associated with an acceptable rejection rate, a good safety profile, and good (graft and native) kidney function; it eliminated undesired calcineurin inhibitor- and steroid-related side effects. Longer follow-up is warranted before expanded application can be recommended.Keywords
This publication has 22 references indexed in Scilit:
- A pilot protocol of a calcineurin‐inhibitor free regimen for kidney transplant recipients of marginal donor kidneys or with delayed graft functionClinical Transplantation, 2003
- Kidney transplantation without calcineurin inhibitor drugs: a prospective, randomized trial of sirolimus versus cyclosporine1Transplantation, 2002
- Steroid Sparing after Kidney and Pancreas TransplantationGraft, 2002
- MULTICENTER TRIAL EXPLORING CALCINEURIN INHIBITORS AVOIDANCE IN RENAL TRANSPLANTATIONTransplantation, 2001
- The CD52 antigen and development of the CAMPATH antibodiesCytotherapy, 2001
- Improving the Outcome of Bone Marrow Transplantation by Using CD52 Monoclonal Antibodies to Prevent Graft-Versus-Host Disease and Graft RejectionBlood, 1998
- Humanised monoclonal antibody therapy for rheumatoid arthritisThe Lancet, 1992
- The CAMPATH‐1 antigen (CDw52)Tissue Antigens, 1990
- Effects of CAMPATH-1 antibodies in vivo in patients with lymphoid malignancies: influence of antibody isotypeBlood, 1989
- ELIMINATION OF GRAFT-VERSUS-HOST DISEASE BY IN-VITRO DEPLETION OF ALLOREACTIVE LYMPHOCYTES WITH A MONOCLONAL RAT ANTI-HUMAN LYMPHOCYTE ANTIBODY (CAMPATH-1)The Lancet, 1984